Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Potential regulatory mechanism and clinical significance of synaptotagmin binding cytoplasmic RNA interacting protein in colorectal cancer
Hui Li, He-Qing Huang, Zhi-Guang Huang, Rong-Quan He, Ye-Ying Fang, Rui Song, Jia-Yuan Luo, Da-Tong Zeng, Kai Qin, Dan-Ming Wei, Gang Chen
Hui Li, Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
He-Qing Huang, Zhi-Guang Huang, Jia-Yuan Luo, Kai Qin, Dan-Ming Wei, Gang Chen, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Rong-Quan He, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Ye-Ying Fang, Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Rui Song, Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Da-Tong Zeng, Department of Pathology, Redcross Hospital of Yulin City, Yulin 537000, Guangxi Zhuang Autonomous Region, China
Co-first authors: Hui Li and He-Qing Huang.
Author contributions: Chen G and Wei DM contributed to the study conception and design; Material preparation, data collection and analysis were performed by Li H, Huang HQ, Huang ZG and He RQ; The first draft of the manuscript was written by Li H, Huang HQ, Fang YY, Song R, Luo JY, Zeng DT and Qin K commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Supported by Guangxi Zhuang Autonomous Region Health Commission Scientific Research Project, No. Z-A20220415 and No. Z20210442; and The First Affiliated Hospital of Guangxi Medical University Provincial and Ministerial Key Laboratory Cultivation Project: Guangxi Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer, No. 21-220-18.
Institutional review board statement: Our study was approved by the medical ethics committee of the First Affiliated Hospital of Guangxi Medical University. The tissue microarray was purchased from Pantomics, Inc. (Richmond, CA, United States), and all the patients had completed the informed consent form.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: The data of this study can be obtained by contacting the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Gang Chen, PhD, Professor, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, No. 22 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
chengang@gxmu.edu.cn
Received: March 24, 2024
Revised: August 17, 2024
Accepted: September 9, 2024
Published online: November 24, 2024
Processing time: 203 Days and 18.6 Hours
BACKGROUND
Colorectal cancer (CRC) causes many deaths worldwide. Synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP) is an RNA-binding protein that plays an important role in multiple cancers by epigenetically targeting some genes. Our study will examine the expression, potential effect, biological function and clinical value of SYNCRIP in CRC.
AIM
To examine the expression, potential effect, biological function and clinical value of SYNCRIP in CRC.
METHODS
The expression of SYNCRIP was examined by immunohistochemistry arrays and high-throughput data. The effect of SYNCRIP gene in CRC cell growth was evaluated by CRISPR-Cas9 technology. The target genes of SYNCRIP were calculated using various algorithms, and the molecular mechanism of SYNCRIP in CRC was explored by mutation analysis and pathway analysis. The clinical value of SYNCRIP in prognosis and radiotherapy was revealed via evidence-based medicine methods.
RESULTS
The protein and mRNA levels of SYNCRIP were both highly expressed in CRC samples compared to nontumorous tissue based on 330 immunohistochemistry arrays and 3640 CRC samples. Cells grew more slowly in eleven CRC cell lines after knocking out the SYNCRIP gene. SYNCRIP could epigenetically target genes to promote the occurrence and development of CRC by boosting the cell cycle and affecting the tumor microenvironment. In addition, CRC patients with high SYNCRIP expression are more sensitive to radiotherapy.
CONCLUSION
SYNCRIP is upregulated in CRC, and highly expressed SYNCRIP can accelerate CRC cell division by exerting its epigenetic regulatory effects. In addition, SYNCRIP is expected to become a potential biomarker to predict the effect of radiotherapy.
Core Tip: Synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP) is regulated by enhancers and POLR2A and highly expressed in colorectal cancer (CRC). Highly expressed SYNCRIP can reduce CD8+ T cells and accelerate CRC cell division by exerting its epigenetic regulatory effects. These CRC cells are sensitive to radiation therapy. Finally, SYNCRIP is expected to become a biomarker in CRC patients.
